Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancerWei Wei, Xiaqin Cheng, Rong Zhang et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 38
Achieving flexible fairness metrics in federated medical imagingZhen Li, Jinke Ren, Chun-Mei Feng et al.|Nature Communications|2025Cited by 18
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.Wei Wei, Min Zheng, Xiaohua Ban et al.|Journal of Clinical Oncology|2021Cited by 2